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Abstract
Cancer care is increasingly becoming challenging in low resource settings. 
With the improved availability and access of generic medicines and biosimi-
lars, cost-effective and affordable treatment can be offered to cancer patients. 
However, generics and biosimilars continue to be plagued with negative percep-
tions that impact the adoption of these products. Lack of understanding and nega-
tive perceptions regarding the quality, safety, effectiveness, integrity and stability, 
formulations, manufacturing, and costs of generics and biosimilars are more 
common in the developing countries. Their equivalence to innovator counterparts 
is often doubted. Collaborative efforts for enhanced utilization of generics and 
biosimilars in oncology should be made by physicians, healthcare professionals, 
manufacturers and sponsors of these drugs, and national healthcare systems. 
Steps to improve access and utilization of these drugs include procurement of 
high-quality generics and biosimilars, formulary management, supply chain 
integrity, continued safety surveillance, and educational programs to improve 
knowledge mitigate fears in healthcare professionals and patients. Objective and 
standard frameworks should be developed and used to identify the perceptions 
and factors impacting the adoption of generics and biosimilars. Outcomes in 
hematological malignancies can be improved with the adoption of generics and 
biosimilars, in particular in low-income countries where access and affordability 
of chemotherapy is challenging.
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1. Introduction
Generic medicines find application in both chemotherapy and supportive care 
in oncology. Generics are increasingly available for small molecules and biologic 
agents used in oncology treatment regimens.
Generic medicines are pharmaceutical drugs that have the same chemical 
substance, i.e., the same active pharmaceutical ingredient (API), as that of the 
originator drug. According to the US Food and Drug Administration (FDA), 
“a generic drug is a medication created to be the same as an existing approved 
brand-name drug in dosage form, safety, strength, route of administration, 
quality, performance characteristics, and intended use [1].” According to the 
European Medicines Agency (EMA), “a generic medicine is developed to be 
the same as a medicine that has already been authorized, called the reference 
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medicine [2].” These regulatory directions of similarity imply the possible 
substitution of innovator products with generic medicines. According to the 
World Health Organization (WHO), a generic is a ‘multisource pharmaceutical 
product which is intended to be interchangeable with the comparator product.’ 
This also includes an originator brand for which the patent has expired. WHO 
has distinguished between originator brand, regardless of its patent status, and 
lowest-priced generic equivalents [3]. Biosimilars are defined as biologic products 
that are highly similar to reference products, notwithstanding minor differences 
in clinically inactive components. Biosimilars have no clinically meaningful 
differences to the reference product in terms of safety profile, purity, and potency 
[4]. Both generics and biosimilars are widely used in cancer care. However, there 
are several differences between the two agents (Table 1) [5].
Generic medicines may differ from the originator products in the manufac-
turing processes. There may be subtle differences in the excipients, color, and 
packaging. Sometimes, generic medicines may also have different formula-
tions. According to the EMA, “a generic medicine’s inactive ingredients, name, 
appearance and packaging can be different [2].” Approval of generics and 
biosimilars are granted after confirmation of evidence of biophysical similarity 
to the originator reference products. This is a proxy to similarity in the clinical 
effectiveness and safety of generics and biosimilars. Generics and biosimilars 
are approved only when there is ‘totality of evidence’ for similarity to the 
reference originator product. This includes robust scientific data for parameters 
of structural analysis, preclinical, pharmacokinetic, efficacy and safety, and 
immunogenicity.
2. Regulations around generics
Various countries have regulations for the development and availability of 
generic medicines. Generic medicines can be marked in a country only after a 
marketing authorization has been obtained. The US FDA requires generics to be 
identical to the originator products in pharmacokinetic and pharmacodynamic 
properties. There are defined parameters for establishment of bioequivalence of 
generic medicines to their branded counterparts. The FDA’s Office of Generic Drugs 
(OGD) has a vigorous review process facilitating the approval of generic medicines 
of high quality [6]. The FDA also has clear directions for the development, review, 
and approval of biosimilars [7]. In the EU, the EMA reviews the quality standards 
and other parameters to establish the equivalence of a generic medicine to its 
innovator counterpart [8]. Various countries have described regulations for the 
production, review, and approval of generics though the regulatory frameworks are 
not equally mature in all countries [9, 10].
Parameter Generic drug Biosimilar
Manufacturing Simple and predictable Stepwise to produce compound as similar as possible 
to the originator biologic
Immunogenicity Low potential No increase in comparison to the reference biologic
Regulatory approvals Small trials in healthy 
volunteers/patients
At least one study including assessments of 
pharmacokinetics, pharmacodynamics, and 
immunogenicity
Table 1. 
Key differences between generic medicines and biosimilar agents.
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3. Use and impact of generics
Generic medicines are increasingly being used in most countries across the 
world. In the US, 9 out of 10 prescriptions are said to have a generic drug [1]. In 
the European Union (EU), about 20–80% prescriptions are filled with generics 
[11]. However, lower utilization of generics is reported in the lesser developed 
countries [12]. Not all generic medicines are available in all countries. Both 
generics and biosimilars are widely used in hematological malignancies. Examples 
include lenalidomide for multiple myeloma, rituximab for Non-Hodgkin’s lym-
phoma, chronic lymphocytic leukemia, and filgrastim for febrile neutropenia.
3.1 Cost reduction
Generic medicines are lesser priced when compared to the innovator products 
and offer affordable options in management of various disease conditions including 
cancer [4, 13]. This has special relevance in low-income countries as it improves 
access and compliance to therapeutic options. Treatment regimens are associated 
with huge costs in oncology settings. The lesser price of generics and biosimilars is 
reflective of the abbreviated pathways to regulatory approvals.
The widespread use of generics has favorably influenced the national health-
care spending. The utilization of generics is influenced by various factors such as 
physician recommendations, pharmacy practices, patient preferences, and the 
economic status of the patient. The use of biosimilars is reported to have an average 
of 20–30% cost-saving effect [14].
3.2 Improved compliance
The affordability of generics and biosimilars offers an opportunity for sustained 
engagement and adherence of patients to the treatment regimens [15]. This is of greater 
relevance in oncology where therapeutic options are expensive and treatments last long 
periods [16]. High costs of treatment are a common impediment in the management of 
cancer. Reduction of costs leads to enhanced access and adoption of generics [17, 18].
4. Perceptions and adoption of generics
Though generic medicines have been available for several decades, there is pau-
city of knowledge about what these medicines are and how these differ from their 
innovator counterparts. There is also a lack of understanding about the standards 
described for the approval and market authorization of generics and how these 
drugs have a lower cost [19].
There are lacunae in knowledge about generics in physicians, healthcare profes-
sionals, and patients. This is evident in the perceptions that healthcare professionals 
and patients have for generics and biosimilars. These perceptions drive the apathy 
or antipathy for generics and impact the adoption of generics in routine practice. 
There are mixed perceptions regarding the use of generic medicines. The percep-
tions differ in various countries. While physicians in the high-income countries 
generally have positive perceptions for generics, those in the low-income countries 
generally have more negative perceptions [12, 20]. Controversies have emerged 
regarding the adoption of generics for brand substitution [21]. The differences in 
perceptions can be attributed to various factors including the regulatory milieu, 
healthcare policies, educational initiatives, and drug information sources.
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Perceptions regarding generics and biosimilars and attitudes of physicians, 
healthcare providers, and patients impact the use of generics (Figure 1). Several 
factors may impact the acceptance and use of generics. These factors are diverse and 
include increased knowledge about the regulated approval of generics and biosimi-
lars and the increased awareness regarding generics from the access to information 
in social and scientific platforms.
Perceptions and levers for adoption of generics may be grouped into four broad 
categories (Figure 2).
4.1 Effectiveness
Though generic medicines have an established equal effectiveness to their 
innovator counterparts and are intended to be interchangeable with the latter, they 
Figure 2. 
Components of perceptions and levers for adoption of generics.
Figure 1. 
Use and adoption of generics and biosimilars. GRAF (generic dRug adoption framework) is a tool to identify 
and differentiate high quality generics.
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are perceived to be less efficacious effective. Physicians and healthcare professionals 
need to understand how confirmation of similar clinical outcomes is key to the reg-
ulatory review process for the approval of generics and biosimilars. Bioequivalence 
is a standard and reliable measure to confirm the similar effectiveness of generics 
and their branded counterparts. Bioequivalence is a dependable proxy for similar 
clinical effects [22]. Therapeutic benefits are maintained when patients receiving 
innovator drugs are switched over to generic options of the same dosing. In the set-
ting of oncology, this switch is not reported to impact the cytogenetic or molecular 
response [23]. The demonstration of equivalence and increasing awareness for the 
same can help physicians and healthcare professionals in easy decision making for a 
switch to generic options.
4.2 Safety
The likely differences in manufacturing and excipients between generics and 
innovator products raise concerns about the safety of generics. Safety is usually 
measured in terms of the number and frequency of adverse effects with the clinical 
use of a pharmaceutical product. There is no established evidence for the inferiority 
of generic medicines for any safety parameters. However, there is a growing trend 
towards the enhanced reporting of safety experiences with generics. This is sugges-
tive of increased surveillance for the safety of generics [24, 25].
Continued safety monitoring is increasingly being applied to generics and bio-
similars. Any efforts made to set up such systems build trust and acceptance for the 
generic molecules. The exposure of generics to stringent pharmacovigilance prac-
tices in the regulated markets are a proxy to established safety of the products. The 
safety monitoring systems in the regulated markets are mature and reliable. These 
systems allow for the easy identification of generics in the reports. For example, in 
the US, the FDA adverse event reporting system (FEARS) enables the identification 
of generic drugs in the safety reporting systems [26]. If approved and marketed in 
countries with such regulations, generic medicines are perceived to hold a promise 
of safety. This facilitates the easy adoption of such approved products.
4.3 Cost
Generic medicines and biosimilars are perceived as low-cost alternatives to 
expensive originator anticancer drugs. Many patients perceive generics as less 
efficacious; physicians and pharmacists continue to doubt the safety of generics 
[27]. These perceptions impact the utilization of generics.
There are smaller price differentials between biosimilars and biopharmaceuti-
cals when compared to generics and their comparator originators. This is explained 
by the longer development time and larger research costs for biosimilars. Cost-
effectiveness and cost-utility analyses are being used to establish the economic 
benefits of adopting biosimilars. Such economic evaluations have a role in checking 
the rapidly rising healthcare expenditures [28]. However, there is a lack of regula-
tory directions for the most appropriate techniques of economic evaluation for 
generics and biosimilars.
The benefits of cost saving options are manifold. Patients may seek affordable 
options, physicians may be reassured by the willingness and ability of patients to 
complete the therapy, and payers may view this as a pharmacoeconomic reform. The 
WHO has described cost of therapy as a key component of rational prescribing [29].
Payers, physicians, and patients are developing an incline to evaluate the phar-
macoeconomics of generics and biosimilars periodically throughout the life cycle 
of the product. This is explained by the increasingly available experience in the 
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real-world settings with these products. Economic efficiency is not solely deter-
mined by the relative costs of generics and comparators. It is ideally defined by the 
attainable levels of efficiency and safety with the use of lower-priced options. This 
eventually constitutes the quality of the generics and biosimilars [30]. In a cost min-
imization study in Colombia, use of generic equivalents of bortezomib, decitabine 
and capecitabine resulted in substantial savings of 63% (USD 4.68 million), 26% 
(USD 0.29 million), and 46% (USD 1.50 million), respectively [31].
4.4 Quality
Quality is a key parameter that impacts the utilization of generics. It is impor-
tant to understand the perceptions about quality of generics and also define what 
parameters define quality of generics.
The regulatory standards for approval of generics and biosimilars are guided 
by the principles of quality by design (QbD) [32]. This implies that science-driven 
and risk-based concepts underlie the development, scale-up, and manufacturing 
of generics and biosimilars. The yield of this approach is a high-quality generic 
product or biosimilar molecule with an implied clinical equivalence which may be 
validated in research studies and clinical experience. Quality is not alone limited 
to structural and chemical similarities during development; it also spans to the 
similarities of generic drugs to comparators in final formulations and packaging. 
Quality is also defined by testing for stability, sterility, and impurities. These data 
are an important and mandatory component of abbreviated new drug applications 
(ANDAs) [33]. The WHO has defined standards for good manufacturing practices 
(GMP) as a guide to the quality assurance of pharmaceutical products [34].
5. Challenges for switch and adoption
With the prevalent perceptions about generics, there are several likely chal-
lenges that physicians and patients can confront for the adoption of these drugs. 
Observational studies have confirmed doubts and unfavorable attitudes in physi-
cians, pharmacists, and lay people for the effectiveness, safety, and quality of 
generic medicines [27]. There may be questions regarding the dependable and 
acceptable evidence for the effectiveness and safety of generics and biosimilars. 
There may be uncertainties regarding the acceptance of bioequivalence as a marker 
of similarity. These uncertainties may lead to cohesive discussions in media and 
scientific platforms which in turn may influence the decision-making for switch 
and substitution with generics and biosimilars.
Physicians may want to go for facility visits to understand and inspect the 
development and manufacturing of generics. This can build trust in the products 
and facilitate their early and easy adoption. Consistent product supply may be taken 
as a proxy to dependable quality and this can safeguard the trust in the product of 
a particular supplier. On the other hand, physicians may feel reassured regarding 
safety if the generic or biosimilar has been approved in a regulated market with 
clear guidance for development and approval of these products.
6. Efforts by companies and physicians
Physicians should make sustained efforts to discuss the most cost-effective 
therapeutic options with patients and help them to achieve desired outcomes at 
lower costs [35, 36]. This may be an important aspect of therapy in low income 
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countries with majority of patients belonging to the poorer segments [37]. Many 
of these countries have ill-defined reimbursement policies and healthcare manage-
ment is largely an out-of-pocket expense. Not alone physicians, pharmacists have an 
important role in the switch and substitution of generics and biosimilars [14].
Company sponsored patient assistance programs (PAP) have a huge potential to 
improve access to generics and biosimilars. These programs offer medicines to eligible 
patients at no or minimal costs [38]. Companies should also make efforts to educate 
patients, inform physicians, and demonstrate benefits to payers for their products.
7. Role of healthcare systems
Healthcare systems should prepare for increased adoption of generics and biosimi-
lars by procurement and formulary management, continued safety surveillance, and 
transformational reforms for mitigating the economic and operational challenges. A 
healthcare system should aim to allow an equitable access to essential medicines of 
assured quality, efficacy, and safety [39]. Policies and programs should aim to not only 
improve access but also build trust in medicine quality and healthcare systems [40].
Procurement of high-quality generics is the first and key step that acts as a 
gatekeeper to the access and adoption of generics and biosimilars in a particular 
country. These practices need to be standardized and implemented as nation-wide 
initiatives for successful utilization of generics. Efforts should be made to develop 
and design a prequalification scheme to assist countries lacking strong regulations 
in procurement of anticancer generics and biosimilars of assured quality [13].
Regulators are making constant efforts to improve the knowledge and under-
standing for the development and clinical use of biosimilars. In collaboration with 
the European Commission, the EMA has formulated an information guide for health-
care professionals to educate them about the development, approval, effectiveness, 
safety, switch, substitution, and interchangeability of biosimilars [8]. Such efforts 
need to be replicated by the healthcare systems in countries with poor regulations. 
Manufacturers can collaborate with the healthcare systems to plan and implement 
educational programs for physicians, pharmacists, and patients. Physicians should 
be educated for the criteria of equivalence, safety and vigilance, and manufacturing 
processes adopted for developing high-quality generics and biosimilars.
There is lack of unawareness for the costs of pharmaceutical therapies in physicians 
[41]. Educational programs should aim to improve understanding for the lower costs 
of generics and biosimilars and the implications of this on overall cost of therapy.
Payers should be encouraged to develop appropriate reimbursement policies that 
will encourage the use of generic medicines in routine clinical practice. Further, a 
pool of generic suppliers should be identified to ensure an uninterrupted availabil-
ity of these medicines [13]. Generic medicines and biosimilars should be included in 
the national lists of essential medicines and should be part of national formularies. 
The integrity of supply chains should be maintained and circulation of counterfeit 
or substandard products should be discouraged. Lack of constant drug supplies 
can lead to mistrust in patients and lack of confidence in physicians and healthcare 
systems. All these factors compromise clinical care in oncology where treatments 
are phased and last longer.
8. Recommendations
Most experience about the knowledge and perceptions regarding generics comes 
from interviews and surveys conducted in cross sections of populations in various 
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countries [12, 27, 42, 43]. There is lack of a standard approach for the assessment of 
knowledge, attitudes, and perceptions about generics. In addition, factors impact-
ing the utilization of generics have not been precisely determined. Sustained and 
collaborative efforts should be made to understand the perceptions for generic 
medicines and mitigate the same.
Educational initiatives should be introduced by manufacturers of generics and 
biosimilars and healthcare systems to improve knowledge about these drugs and 
develop positive attitudes towards their adoption. This will empower physicians, 
patients, and pharmacists to make rational choices in therapy and improve out-
comes of cancer care.
Uniform standards should be developed for high-quality generics and these need 
to be implemented at global levels. Maiden efforts in this direction include tools 
like the generic dRug adoption framework (GRAF) (Figure 1). This framework, 
comprising a 20-item questionnaire, has been developed to enable physicians and 
pharmacists to make decisions to identify and differentiate high quality generics 
and facilitate interchangeability. Currently available in three languages (English, 
Spanish, and Portuguese), the framework has successfully been implemented in 
Brazil and Colombia. More and more countries should adopt such objective mea-
sures to evaluate the perceptions and adoption of high-quality generics. Insights 
gained from the experience of such frameworks can help to make further reforms 
to allow the identification, procurement, and prescription of high-quality generic 
medicines. This can advance the use of cost-effective solutions in cancer care.
9. Conclusions
Availability of generics and easier access to these drugs can impact the out-
comes in oncology settings. The low-priced and affordable generic medicines and 
biosimilars can improve the adoption and compliance with treatment options in 
cancer care. However, the low price of these drugs is often construed as compromise 
in quality. There are myriad perceptions for the use of generics and biosimilars 
in routine practice. The perceptions are different among physicians in high- and 
low-income countries; these can possibly be due to differences in regulations and 
policies, educational opportunities and available drug information sources. Factors 
like cost, quality, effectiveness, and safety impact the understanding for and adop-
tion of generics and biosimilars. There are several challenges in the substitution and 
switch from originator products to generics and biosimilars. The widespread and 
confident adoption of generics requires collaborative efforts of prescribers, health-
care professionals, payers, and the manufacturers of these agents.
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